Programmable lipid nanoparticles for RNA therapeutics: Design principles and clinical translation

Area of Science:

• Biotechnology
• Nanomedicine
• Molecular Biology

Background:

• RNA therapeutics (mRNA, siRNA, ASOs) are clinically validated.
• Lipid nanoparticles (LNPs) are the primary non-viral delivery system.
• Programmable LNPs offer tunable control over delivery characteristics.

Purpose of the Study:

• To define programmable LNPs and their design principles.
• To review advances in LNP formulation, manufacturing, and characterization.
• To analyze applications, translational challenges, and success factors for LNP-based RNA medicines.

Main Methods:

• Summarizing design rules for LNP components (ionizable lipid, phospholipid, cholesterol, PEG-lipid).
• Highlighting formulation strategies like pKa optimization, biodegradable linkers, ligands, and SORT lipids.
• Surveying data-guided formulation, scalable manufacturing techniques, and quality control.

Main Results:

• Programmable LNPs can be engineered for specific organ tropism and cell targeting.
• Advances in formulation and manufacturing enable scalable production and rigorous characterization.
• Successful clinical applications include vaccines, protein replacement, and gene editing.

Conclusions:

• Programmable LNPs provide a versatile platform for extrahepatic and cell-specific RNA medicine delivery.
• Rigorous analytics, platform manufacturing, and understanding translational constraints are crucial for success.
• Optimized LNP design facilitates potent and efficient RNA therapeutics with reduced lipid burden.